Navigation Links
Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
Date:4/7/2008

ical need for patients with medical conditions and those patients seeking safer alternatives to the standard pain management approaches.

In the second quarter of 2008, the Company intends to initiate the randomized, double-blind, placebo controlled Phase 3 program to evaluate the efficacy and safety of Ketotransdel in acute pain care management. The Company also stated that in the near term it will be announcing organizational changes as the company transitions into late stage clinical phase.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel, utilizes the Company's innovative patented Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug can exert its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially fr
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)... 19, 2013  Decision Resources, one of the ... and healthcare issues, finds that, for the treatment ... and European rheumatologists cite a therapy,s induction of ... influences their prescribing decisions. Over 60 percent and ... rank the percentage of patients achieving remission at ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") ... results for the first quarter ended March 31, 2011. ... million through two financings, advanced pixantrone into a confirmatory ... Therapeutics Ltd. ("Chroma") to co-develop and market Chroma,s drug ...
... April 26, 2011 BD (Becton, Dickinson and Company) ... technology company, today reported quarterly revenues of $1.922 billion ... representing an increase of 6.8 percent from the prior-year ... percent, despite an unfavorable comparison to the prior year ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6BD Announces Results for 2011 Second Fiscal Quarter 2BD Announces Results for 2011 Second Fiscal Quarter 3BD Announces Results for 2011 Second Fiscal Quarter 4BD Announces Results for 2011 Second Fiscal Quarter 5BD Announces Results for 2011 Second Fiscal Quarter 6BD Announces Results for 2011 Second Fiscal Quarter 7BD Announces Results for 2011 Second Fiscal Quarter 8BD Announces Results for 2011 Second Fiscal Quarter 9BD Announces Results for 2011 Second Fiscal Quarter 10BD Announces Results for 2011 Second Fiscal Quarter 11BD Announces Results for 2011 Second Fiscal Quarter 12BD Announces Results for 2011 Second Fiscal Quarter 13BD Announces Results for 2011 Second Fiscal Quarter 14
(Date:6/19/2013)... June 19 online edition of the journal Nature ... University of California, San Diego School of Medicine visually ... cardiac regeneration occurs in zebrafish after cardiac ventricular injury. ... in the heart are more plastic, or capable of ... More importantly, the research reveals a novel potential source ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... significant disparities between minority and white clients in ... Moreover, these disparities vary widely from state to ... most states there,s something amiss," says Stephan Arndt, ... are strong racial and ethnic disparities for people ... programs successfully, and those disparities are something we ...
(Date:6/19/2013)... In early April, senior leaders from medical, law ... to discuss one question: how can first responders improve ... The preliminary results of this discussion are now available ... Hartford Consensus ," a concept paper published in the ... Trauma and Acute Care Surgery , official publication ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on at ... take two, Mayo Clinic researchers say. Antibiotics, antidepressants ... study found. Twenty percent of patients are on ... findings, published online in the journal Mayo ... and video of Dr. Jennifer St. Sauver talking ...
Breaking Medicine News(10 mins):Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... science and progress of integrative medicine in the ... convene the "Summit on Integrative Medicine and the ... D.C. The summit will bring together distinguished researchers, ... the vision, challenges, evidence base, and opportunities for ...
... Control Weight Permanently , MIDLAND, Mich., Jan. 27 ... is the challenge. With this Health Enhancement Systems ... Healthy Weight for Life ( ... gain control of their weight -- and improve their health ...
... the fight against,oral cancer is now being offered by Barotz ... http://www.barotzdental.com , determines a,person,s risk for oral cancer disease in ... Americans are diagnosed with oral cancer each year. While,easy ... death rate,because it is routinely discovered late in its development," ...
... of the European Heart Rhythm Association (EHRA), is today ... More than 4,000 participants are expected to attend this ... and sudden cardiac death. , EHRA is a registered ... mission is to reduce the impact of cardiac arrhythmias ...
... Meanwhile, U.S. officials say illnesses linked to tainted peanut ... 27 (HealthDay News) -- The Georgia facility that produced ... nationwide salmonella outbreak has a history of health-inspection violations, ... officials reported Monday that the outbreak, which has now ...
... Forever" Solution , , DALLAS, Jan. 27 ... it,s swept under the rug as a nuisance. However, ... an indicator of a serious health problem called obstructive sleep ... of Plano is announcing a dental approach to end snoring ...
Cached Medicine News:Health News:IOM gathers health care leaders for summit on integrative medicine 2Health News:Thousands Look Better, Feel Better, and Have More Energy Because of NutriSum 2Health News:Barotz Dental Offers Free Online Oral Cancer Risk Assessment 2Health News:EUROPACE 2009 2Health News:Salmonella Outbreak Site Has History of Health Violations: Report 2Health News:Spouses of the Lone Star State Rejoice As Snoring Is DOA 2
For determination of triglycerides in serum or plasma. For Hitachi 704 / 911. Available with calibrator: Trucal U and also with controls: Trulab N, Trulab P, Trulab L....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
For the quantitative determination of triglycerides in serum. Linearity: 1000 mg/dl....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Medicine Products: